Novartis Self-Medication's lead OTC manufacturing facility will be in Lincoln, Neb.
This article was originally published in The Tan Sheet
Executive Summary
NOVARTIS SELF-MEDICATION MANUFACTURING WILL BE BASED IN LINCOLN, NEB. following the merger of Ciba-Geigy and Sandoz, the companies announced Oct. 17. The Sandoz manufacturing site in Lincoln will absorb the majority of the OTC production currently handled by Ciba's facility in Fort Washington, Pa.
You may also be interested in...
Novartis R&D
Novartis has opened an OTC Research & Development center in Mumbai, India that is "currently working on various conventional and innovative dosage forms," the company announces Feb. 22. The center increases the firm's pharmaceutical development capacity by around 25%, the firm said. Novartis runs two other centers in Nyon, Switzerland and Lincoln, Neb. (1"The Tan Sheet" Oct. 21, 1996, p. 10). The facility will develop OTC drugs, including products for cough/cold, allergies, smoking cessation, gastrointestinal disorders, dermal infections and nutritional supplements. The center employs 35 associates, draws on the "expertise and skills" available in the country and "expands the company's presence in a country that is rapidly becoming a dominant force in the international marketplace," Novartis states...
Novartis R&D
Novartis has opened an OTC Research & Development center in Mumbai, India that is "currently working on various conventional and innovative dosage forms," the company announces Feb. 22. The center increases the firm's pharmaceutical development capacity by around 25%, the firm said. Novartis runs two other centers in Nyon, Switzerland and Lincoln, Neb. (1"The Tan Sheet" Oct. 21, 1996, p. 10). The facility will develop OTC drugs, including products for cough/cold, allergies, smoking cessation, gastrointestinal disorders, dermal infections and nutritional supplements. The center employs 35 associates, draws on the "expertise and skills" available in the country and "expands the company's presence in a country that is rapidly becoming a dominant force in the international marketplace," Novartis states...
Novartis R&D
Novartis has opened an OTC Research & Development center in Mumbai, India that is "currently working on various conventional and innovative dosage forms," the company announces Feb. 22. The center increases the firm's pharmaceutical development capacity by around 25%, the firm said. Novartis runs two other centers in Nyon, Switzerland and Lincoln, Neb. (1"The Tan Sheet" Oct. 21, 1996, p. 10). The facility will develop OTC drugs, including products for cough/cold, allergies, smoking cessation, gastrointestinal disorders, dermal infections and nutritional supplements. The center employs 35 associates, draws on the "expertise and skills" available in the country and "expands the company's presence in a country that is rapidly becoming a dominant force in the international marketplace," Novartis states...